No Survival Gain From High-Dose Cytarabine Consolidation in AML

The real-world registry data backup findings from randomized trials comparing high vs intermediate doses. The study was published as a preprint and has not yet been peer reviewed.
First Look

source https://www.medscape.com/viewarticle/976065?src=rss